Literature DB >> 12919182

Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids.

Dennis A Hesselink1, Hien Ngyuen, Marike Wabbijn, Peter J H Smak Gregoor, Ewout W Steyerberg, Iza C van Riemsdijk, Willem Weimar, Teun van Gelder.   

Abstract

AIMS: To evaluate the effect of corticosteroids on tacrolimus pharmacokinetics.
METHODS: In a randomized trial, kidney transplant recipients were treated with tacrolimus and mycophenolate mofetil with either daclizumab (n = 31) or 3 months of prednisone (n = 34). Tacrolimus dose-adjusted predose concentrations (C0) at month 1-6 were compared between both groups and within the corticosteroid group before and after prednisone withdrawal.
RESULTS: At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group. The tacrolimus dose-adjusted C0 within the corticosteroid group at month 1 and 2 was 42% and 29% lower compared with month 4 (P < 0.001).
CONCLUSIONS: A higher tacrolimus dose is required to reach target concentrations when used in combination with corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919182      PMCID: PMC1884345          DOI: 10.1046/j.0306-5251.2003.01882.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Clinical management of tacrolimus drug interactions in renal transplant patients.

Authors:  M Moreno; A Latorre; C Manzanares; E Morales; J C Herrero; B Dominguez-Gil; A Carreño; A Cubas; M Delgado; A Andres; J M Morales
Journal:  Transplant Proc       Date:  1999-09       Impact factor: 1.066

2.  Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients.

Authors:  C J Hesse; C C Baan; A H M M Balk; H J Metselaar; W Weimar; T van Gelder
Journal:  Transplant Proc       Date:  2002-11       Impact factor: 1.066

3.  Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study.

Authors:  Jean-Paul Squifflet; Y Vanrenterghem; J P van Hooff; K Salmela; P Rigotti
Journal:  Transplant Proc       Date:  2002-08       Impact factor: 1.066

Review 4.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients.

Authors:  K L Tortorice; K L Heim-Duthoy; W M Awni; K V Rao; B L Kasiske
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

6.  Nifedipine interaction with tacrolimus in liver transplant recipients.

Authors:  R A Seifeldin; A Marcos-Alvarez; F D Gordon; W D Lewis; R L Jenkins
Journal:  Ann Pharmacother       Date:  1997-05       Impact factor: 3.154

7.  Renal allograft dysfunction associated with rifampin-tacrolimus interaction.

Authors:  R Y Chenhsu; C C Loong; M H Chou; M F Lin; W C Yang
Journal:  Ann Pharmacother       Date:  2000-01       Impact factor: 3.154

8.  Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes.

Authors:  U Christians; G Schmidt; A Bader; A Lampen; R Schottmann; A Linck; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  1996-03       Impact factor: 4.335

Review 9.  Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

Authors:  C J Dunn; A J Wagstaff; C M Perry; G L Plosker; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 10.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

View more
  13 in total

1.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.

Authors:  Tania Claeys; Maria Van Dyck; Rita Van Damme-Lombaerts
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

3.  Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.

Authors:  Pamala A Jacobson; William S Oetting; Ann M Brearley; Robert Leduc; Weihau Guan; David Schladt; Arthur J Matas; Vishal Lamba; Bruce A Julian; Rosalyn B Mannon; Ajay Israni
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

4.  The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study.

Authors:  Neven Vavic; Nemanja Rancic; Viktorija Dragojevic-Simic; Biljana Draskovic-Pavlovic; Dubravko Bokonjic; Ljiljana Ignjatovic; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-20       Impact factor: 2.441

5.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.

Authors:  P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

7.  The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.

Authors:  Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 8.  Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors:  Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Authors:  Dirk R J Kuypers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 10.  Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).

Authors:  Christiane Pauli-Magnus; Deanna L Kroetz
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.